Safety and efficacy of subcutaneous tocilizumab for patients with systemic-onset juvenile idiopathic arthritis

Safety and efficacy of subcutaneous tocilizumab for patients with systemic-onset juvenile idiopathic arthritis - Safety and efficacy of subcutaneous tocilizumab for patients with systemic-onset juvenile idiopathic arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023036

Enrollment

Registered

2016-07-06

Start date

2016-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic-onset juvenile idiopathic arthritis(sJIA)

Interventions

Switch intravenous to Subcutaneous TCZ 162mg/1-2week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. sJIA patients treated with TCZ 2. Extended TCZ interval 2weeks to 4weeks 3. In remission maintenance

Exclusion criteria

Exclusion criteria: 1. Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2. Infection of HIV, HCV or HBV 3. Pregnant subjects or subjects who do not agree with contraception during the study period

Design outcomes

Primary

Measure	Time frame
Maintenance of remission	—

Secondary

Measure	Time frame
Improvement of QOL	—

Countries

Japan

Contacts

Public ContactKenichi Nishimura

Yokohama city university Pediatrics

ken_1_0306@hotmail.com045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026